High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma
Youngun Kim, Hannah Yang, Won Suk Lee, Jaekyung Cheon, Yun Beom Sang, Beodeul Kang, Hong Jae Chon, Chan Kim
Abstract
T cells were significantly lower in patients with high serum IL-10 levels, who also had a shorter duration of response to first-line ICI therapy (4.6 months vs. not reached, P < 0.001). In conclusion, elevated serum IL-10 levels at baseline were associated with reduced clinical benefit from first-line ICI therapy in patients with advanced RCC.
Topics & Concepts
MedicineRenal cell carcinomaInternal medicineBiomarkerGastroenterologyOncologyProportional hazards modelCD8CytokineInterleukin 2ImmunotherapyImmune systemCancerImmunologyBiologyBiochemistryRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis